Calprotectin and platelet aggregation in patients with stable coronary artery disease

• Published in: PloS one 2015-05, Vol.10 (5), p.e0125992-e0125992
• Main Authors: Larsen, Sanne Bøjet, Grove, Erik Lerkevang, Pareek, Manan, Kristensen, Steen Dalby, Hvas, Anne-Mette
• Format: Article
• Language: English
• Subjects: Activation; Aged; Agglomeration; Arachidonic acid; Aspirin; Aspirin - therapeutic use; Atherosclerosis; Blood platelets; Body mass; Body mass index; Body size; C-Reactive Protein - metabolism; Cardiology; Cardiovascular disease; Care and treatment; Collagen; Coronary artery; Coronary artery disease; Coronary Artery Disease - blood; Coronary Artery Disease - drug therapy; Coronary Artery Disease - physiopathology; Coronary heart disease; Coronary vessels; Cross-Sectional Studies; Cyclooxygenase-1; Diabetes; Diabetes mellitus; Diagnosis; Dosage and administration; Enzyme-linked immunosorbent assay; Female; Health sciences; Heart attacks; Heart diseases; Heart surgery; Hematology; Hospitals; Humans; Inflammation; Interleukin; Interleukin 6; Interleukin-6 - blood; Laboratories; Leukocyte L1 Antigen Complex - blood; Leukocytes; Male; Medication Adherence; Middle Aged; P-selectin; Pathogenesis; Patients; Platelet Aggregation; Platelet Aggregation Inhibitors - therapeutic use; Proteins; Quality; Risk; Risk factors; Smoking; Studies; Therapy; Thromboxane B2 - blood; Type 2 diabetes; Unsaturated fatty acids; Weight control
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0125992

Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD). However, the impact of calprotectin levels on platelet aggregation in CAD patients has never been investigated. We investigated the association between calprotectin levels and platelet aggregation in stable, high-risk CAD patients receiving aspirin as mono antiplatelet therapy. Furthermore, we aimed to investigate independent clinical and laboratory determinants of calprotectin levels. We performed a cross-sectional study including 581 stable, high-risk CAD patients. All patients received 75 mg aspirin daily as mono antiplatelet therapy. Platelet aggregation was assessed by 1) impedance aggregometry (Multiplate Analyzer) using arachidonic acid (AA) and collagen as agonists and by 2) the VerifyNow Aspirin Assay. Low-grade inflammation was evaluated by calprotectin, high-sensitive C-reactive-protein (hs-CRP) and interleukin-6. Platelet activation was assessed by soluble P-selectin, and cyclooxygenase-1 inhibition was evaluated by serum thromboxane B2, both measured by ELISA. Calprotectin levels correlated positively with platelet aggregation according to Multiplate Analyzer (r=0.12, p=0.01). Additionally, calprotectin was positively associated with leukocytes (r=0.33, p